Technical Analysis for OXB - Oxford Biomedica Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 228.50 | 3.86% | 8.50 |
Earnings due: Apr 29
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Slingshot Bullish | Bullish Swing Setup | 3.86% | |
| Upper Bollinger Band Walk | Strength | 3.86% |
| Alert | Time |
|---|---|
| Up 1 ATR | 1 day ago |
| Up 5% | 1 day ago |
| Up 3% | 1 day ago |
| Gap Down Closed | 1 day ago |
| Reversed from Down | 1 day ago |
Free Daily (Stock) Chart Reading
Oxford Biomedica Plc Description
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Pipe Diseases Xf Therapy Cell Therapy Cancers Parkinson's Disease Platform Technology Gene Delivery Bioprocessing Cell Therapy Product Viral Vector Virotherapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 474.28 |
| 52 Week Low | 164.288 |
| Average Volume | 314,413 |
| 200-Day Moving Average | 242.96 |
| 50-Day Moving Average | 193.86 |
| 20-Day Moving Average | 205.56 |
| 10-Day Moving Average | 209.01 |
| Average True Range | 10.66 |
| RSI (14) | 70.33 |
| ADX | 28.82 |
| +DI | 29.72 |
| -DI | 9.22 |
| Chandelier Exit (Long, 3 ATRs) | 202.02 |
| Chandelier Exit (Short, 3 ATRs) | 219.81 |
| Upper Bollinger Bands | 223.58 |
| Lower Bollinger Band | 187.53 |
| Percent B (%b) | 1.14 |
| BandWidth | 17.53 |
| MACD Line | 6.89 |
| MACD Signal Line | 4.71 |
| MACD Histogram | 2.1802 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 258.58 | ||||
| Resistance 3 (R3) | 257.07 | 245.53 | 253.56 | ||
| Resistance 2 (R2) | 245.53 | 237.87 | 246.29 | 251.89 | |
| Resistance 1 (R1) | 237.02 | 233.14 | 241.28 | 238.53 | 250.22 |
| Pivot Point | 225.48 | 225.48 | 227.61 | 226.24 | 225.48 |
| Support 1 (S1) | 216.97 | 217.82 | 221.23 | 218.48 | 206.78 |
| Support 2 (S2) | 205.43 | 213.09 | 206.19 | 205.11 | |
| Support 3 (S3) | 196.92 | 205.43 | 203.44 | ||
| Support 4 (S4) | 198.43 |
